Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors

The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.

NCT Number	NCT07743827
Lead Sponsor	Alexandria University
Conditions	Olanzapine, Breast Cancer, Dexamethasone
Enrollment	90 participants
Start Date	2026-05-10
Primary Completion	2027-09-29 (estimated)
Study Completion	2027-10-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-04